Entries |
Document | Title | Date |
20080199892 | Process for Screening Glycoform-Specific Antibodies - The present invention relates to the use of the assessment of the binding between—antibodies elicited against a first glycoprotein, and—at least one glycoform of a second glycoprotein, said second glycoprotein being itself a glycoform of the first protein, wherein said glycoform of the second glycoprotein is selected from a group of glycoforms of the second glycoprotein, each glycoform of said group corresponding to a determined glycosylation state defined by a determined sialylation state, and/or a determined branching state, and/or a determined fucosylation state, provided that said glycosylation state is not uniquely defined by a substantially unsialylated state, for the screening of glycoform specific antibodies directed against a given glycoform of the second glycoprotein. | 08-21-2008 |
20080206797 | Csf Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases - CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals. | 08-28-2008 |
20080248509 | METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE WITH DETERMINATION OF LASP-1 IMMUNOREACTIVITY - Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined. | 10-09-2008 |
20080248510 | HUMAN Fc GAMMA RECEPTOR III - The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells. | 10-09-2008 |
20080261253 | Methods and kits for the diagnosis of galactosemia - Provided are methods for the detection and diagnosis of galactosemia. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of galactosemia. At least two new biomarkers for galactosemia are thus disclosed, Eotaxin and MCP-1. Altogether the concentrations these markers, individually, or in combinations with any of Alpha-2 Macroglobulin, Apolipoprotein H, Cancer Antigen 125, Leptin, TNF RII, Alpha-Fetoprotein, IgM, MIP-1 alpha, Ferritin, and IgE provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from galactosemia. Kits containing reagents to assist in the analysis of fluid samples are also described. | 10-23-2008 |
20080280311 | Immunoassay for the Simultaneous Immunochemical Determination of an Analyte (Antigen) and a Treatment Antibody Targeting the Analyte in Samples (Recovery Immunoassay) - The invention relates to an immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay). The inventive immunoassay comprises an optionally marked catcher antibody bound to a surface, a marked treatment antibody, or a marked antibody which has the same binding epitope as the treatment body, an antigen that binds to the catcher antibody and the treatment antibody in the region of various epitopes, and in this way forms an immunochemical sandwich, a solution of the unmarked treatment antibody of a known concentration, and an antigen solution to be added to the samples. The invention can be applied to the fields of medical diagnosis, treatment control and pharmacological research. | 11-13-2008 |
20080311604 | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors. | 12-18-2008 |
20090017480 | BIOAMPLIFICATION FOR MICROBIAL SENSOR SIGNAL TRANSDUCTION - A process of detection of the causative agent of Johne's disease ( | 01-15-2009 |
20090029396 | Assay kit and antibody for human low molecular weight CD14 - The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis. | 01-29-2009 |
20090029397 | Method for Monitoring Tocolytic Treatment - A method of monitoring tocolytic therapy in a pregnant woman. The method comprises determining a first concentration of placental protein 13 (PP13) in a bodily substance of a woman who has not received treatment with a tocolytic agent, determining a second concentration of PP13 in a bodily substance of the pregnant woman after initiation of treatment with a tocolytic agent, and comparing the second concentration with the first concentration. Based on the comparison, it may be determined whether to continue, discontinue, or modify the tocolytic treatment. | 01-29-2009 |
20090061467 | Methods and Compositions for Measuring Canine BNP and Uses Thereof - The present invention describes compositions and methods designed to determine the presence or amount of BNP or fragments thereof in a sample. In particular, the invention provides materials that may be configured to bind canine BNP in a sandwich assay format. The present invention provides, inter alia, assays designed to rapidly and accurately measure BNP-related species in non-human animals. | 03-05-2009 |
20090087868 | Neural Proteins as Biomarkers for Nervous System Injury and Other Neural Disorders - The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury. | 04-02-2009 |
20090087869 | SANDWICH IMMUNOASSAY AND METHOD OF DETECTING AN ANTIGEN BY USING THE SAME - The invention provides a method of sandwich immunoassay comprising steps of, (a) forming a complex of an antigen and a first antibody by contacting the antigen with the first antibody which recognizes the antigen and which is labeled by a detectable labeling substance; and (b) fixing the complex formed in the step (a) to a solid phase by using a second antibody which recognizes the antigen and which is capable of binding to the solid phase, as well as a method for detecting an antigen in an analyte by using a method of sandwich immunoassay. | 04-02-2009 |
20090117597 | Method for Measuring Heptoglobin Level in Blood Serum and Kit Therefor - The present invention relates to a method for measuring heptoglobin level in blood serum by using antibodies for α and β subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for α and β subunits of heptoglobin for measuring heptoglobin level in blood serum. A method for measuring heptoglobin level in blood serum of the present invention comprises the steps of: reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody (βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; and, measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 100 kDa. The method for measuring heptoglobin level in blood serum can be practically applied for the early diagnosis of diseases which disrupt erythrocytes, since only the level of normal heptoglobin except for monomelic and degraded hep-toglobins can be specifically measured by the said method. | 05-07-2009 |
20090123952 | Method of Measuring Amyloid-Beta Peptides - The present invention relates to methods for measuring Aβ peptides in a sample, particularly a sample of blood, such as whole blood and plasma, and to methods of determining whether a compound alters the amount of Aβ produced by a cell or animal. | 05-14-2009 |
20090136973 | DETERMINATION OF SHORT-CHAIN SRL ALCOHOL DEHYDROGENASE (DHRS4) AS A BIOMARKER FOR INFLAMMATIONS AND INFECTIONS - The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections. | 05-28-2009 |
20090142783 | Human p51 Genes and Gene Products Thereof - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1. | 06-04-2009 |
20090162878 | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPB - The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided. | 06-25-2009 |
20090176259 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN - Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as botulinum neurotoxin, | 07-09-2009 |
20090215096 | Collodial silica particle containing light-absorbing susbstance, nano light-absorbing material,absorption labeling nanobead kit, and method for detection or quantification of biological molecule using the colloidal silica particle containing light-absorbing substance - A colloidal silica particle containing a light-absorbing substance, comprising a colloidal silica particle and a light-absorbing substance distributed over the colloidal silica particle, wherein the light-absorbing substance is chemically bound to or adsorbed on a silica component. | 08-27-2009 |
20090221009 | Diagnostic Method for Disorders Using Copeptin - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases. | 09-03-2009 |
20090221010 | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors. | 09-03-2009 |
20090263840 | Novel Monoclonal Anitbody and Use thereof - The present invention provides an antibody capable of specifically recognizing the same amino acid sequence as an antigenic determinant of mouse monoclonal antibody MAB-ME-16F4.3 (FERM BP-10329), and an antibody of capable of specifically recognizing the same amino acid sequence as an antigenic determinant of mouse monoclonal antibody MAB-ME-12C9.2 (FERM BP-10328), and methods of risk prediction of bone fracture and/or diagnosis of osteoporosis by detecting a MEPE-derived molecule in a biological sample using the above-mentioned two kinds of antibodies. | 10-22-2009 |
20090280513 | COMPOSITIONS AND METHODS FOR DETECTION, PREVENTION, AND TREATMENT OF ANTHRAX AND OTHER INFECTIOUS DISEASES - Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods of immunizing humans or animals against | 11-12-2009 |
20090291462 | Detection or Quantification of Aggrecan and its Fragments - An immunoassay for aggrecan and/or aggrecan derived fragments comprises contacting a sample with an immunological binding partner which has specific binding affinity for the G2 domain of aggrecan at least when bearing keratan sulphate chains, and determining the existence or amount of specific binding of the immunological binding partner, which may be conducted as a sandwich assay using a first antibody that binds an N-terminal amino acid sequence comprising FFGVG . . . and a second antibody that binds an N-terminal amino acid sequence comprising ARGS. | 11-26-2009 |
20090311728 | Novel Platelet Activation Marker and Method for Determination Thereof - The present invention provides a convenient and highly sensitive method of determining sGPVI present in plasma; this is accomplished by establishing a plurality of mouse hybridomas that produce antibody against GPVI and combining the antibodies produced therefrom. Provided thereby are a novel platelet activation marker, a reagent and method for determining this novel platelet activation marker, and novel applications of this marker in, for example, the diagnosis of diseases associated with platelet activation/vascular endothelial injury. | 12-17-2009 |
20090311729 | DIAGNOSIS OF ACUTE ENTEROCOLITIS BY DETERMINATION OF INTESTINAL FATTY ACID-BINDING PROTEIN IN THE BLOOD - The present invention provides a quick and convenient determination method and a determination reagent for acute enterocolitis, which can determine acute enterocolitis quantitatively and objectively. | 12-17-2009 |
20090317845 | Impulsive Noise Sensor - The present invention provides a method for measuring the presence of an analyte in a sample, wherein the presence of the analyte is indicated by the presence or absence of one or more trigger elements that generate an impulsive noise when triggered, comprising the steps of: (a) exposing the one or more trigger elements to a triggering impulse; and (b) detecting the impulsive noise generated by said one or more trigger elements. The present invention further provides reagents that can be used in the method of the present invention. | 12-24-2009 |
20100009394 | UNIVERSAL TANDEM SOLID-PHASES BASED IMMUNOASSAY - Universal tandem solid-phases based immunoassay (UTSIA) is a sandwich-ELISA equivalent assay for low abundance antigen determination that overcomes limitations of sandwich-ELISA (antibody inactivation by solid phase and strict requirement of a pair of primary and secondary antibodies) by using an affinity binding solid phase to capture antigen specifically from a fluid sample, sequentially dissociating the antigen, transferring, and coating the antigen to a non-affinity binding solid phase for specific antigen determination. Cell-based UTSIA is a cell-based ELISA equivalent assay that overcomes limitations of image method for determining an antigen in the cells or tissue immobilized on a solid phase by dissociating and transferring the detection antibody bound on the antigen of the cells or tissue immobilized on the solid phase to a second solid phase and immobilizing the detection antibody there for specific detection of the antigen via the detection of the detection antibody. | 01-14-2010 |
20100035286 | IN VITRO METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS - In vitro method for the detection and early detection of, for the determination of the degree of severity of, and for the assessment of the course of and prognosis of neurodegenerative disorders, in which an immunodiagnostic determination method is used to determine the apolipoprotein C-1 (Apo C-1) immunoreactivity in a serum or plasma sample from a patient suffering from subjective or objectively verifiable cognitive disorders. | 02-11-2010 |
20100047832 | Assessment of Patients with Sepsis to Determine a Requirement for Therapeutic Intervention with an Anti-Inflammatory and/or Anticoagulatory Agent - Methods of selecting patients with sepsis for treatment with an anti-inflammatory and/or anticoagulatory agent are provided. | 02-25-2010 |
20100062463 | IN VITRO MULTIPARAMETER DETERMINATION METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS - In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found. | 03-11-2010 |
20100068738 | Method of Immunoassaying A Component to be Measured - A method of immunoassaying a component to be measured in a sample containing hemoglobin, which comprises reacting a component to be measured in a sample containing hemoglobin with an antibody capable of binding to the component in the presence of a bile acid derivative different from a bile acid derivative that is inherently contained in the sample; a method of suppressing an interference of hemoglobin in immunoassaying a component to be measured in a sample containing hemoglobin, which comprises reacting a component to be measured in a sample containing hemoglobin with an antibody capable of binding to the component in the presence of a bile acid derivative different from a bile acid derivative that is inherently contained in the sample; a reagent of immunoassay of a component to be measured in a sample containing hemoglobin, which comprises a bile acid derivative, are described. | 03-18-2010 |
20100093007 | Method of Diagnosis of Tuberculosis Related Immune Restoration Syndrome (IRS) - The present invention relates to a method and kit of diagnosis of Immune Restoration Syndrome associated with tuberculosis (TB-IRS) in patients infected with tuberculosis (TB) as well as in HIV co-infected patients comprising detecting an acute increase in Th1 response following exposure to mycobacterial extract, referred as tuberculin or PPD (Purified Protein Derivative) as well as to the 16 kDa protein, but not to ESAT-6 or CFP-10, two antigens from | 04-15-2010 |
20100105089 | QUANTUM DOT BIOTAGS - A biotag that includes a biomolecule that includes a bio polymer sequence; an attaching polymer attached at an endpoint of the biopolymer sequence; and a quantum dot bound to the attaching polymer causing the attaching polymer to become fluorescently labeled is provided. Suggested biomolecules include, but are not limited to, peptides, proteins, amino acids, nucleic acids, deoxyribonucleic acids, ribonucleic acids, and peptide nucleic acids. The biopolymer sequence may be or otherwise include a protein sequence. The biomolecule may be located inside a cell, outside a cell, or on a cell. Desirably, a quantum dot is bound to an attaching polymer and, thus the biomolecule, without using any of thiol chemistries, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide/N-hydroxysuccinimide hydrochloride (EDC/NHS) chemistries, and biotin/avidin chemistries. In certain desirable embodiments, the attaching polymer is attached at an endpoint of a biopolymer sequence using any of synthesizing, replicating, transcribing, translating, and expressing the attaching polymer at any of a C-terminal end or an N-terminal end of the biopolymer sequence. | 04-29-2010 |
20100124756 | COLLECTION OF BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ALZHEIMER'S DISEASE IN BODY FLUIDS - The inventors have discovered sets of proteinaceous biomarkers (“AD biomarkers”) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease. The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating the levels of the AD biomarkers. | 05-20-2010 |
20100129839 | Method for in vitro diagnosis of pvl-producing staphylococcus aureus - The present invention relates to a method for in vitro diagnosis of | 05-27-2010 |
20100143953 | DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY BY MEANS OF NATRIURETIC PEPTIDES FOR NYHA I PATIENTS - The invention relates to a method for the diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency for NYHA I patients, wherein a determination of the proANP marker, NT-proANP marker, or fragments or partial peptides thereof is carried out parallel to a determination of BNP, proBNP, and/or NT-proBNP on patients to be examined. | 06-10-2010 |
20100143954 | Galectin-3 Immunoassay - The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration. | 06-10-2010 |
20100159492 | Method for the Diagnosis of Diseases by Determining Apolipoprotein C-1 - A method for the diagnosis, early detection, risk estimation and control of the course of diseases, wherein the amount of apolipoprotein C-I and/or derivatives thereof is determined in a serum or plasma sample from a human patient and it is possible to conclude as to the presence of a disease, particular a tumoral disease or sepsis, on the basis of a result deviating significantly from the value range determined for normal healthy persons. The invention also relates to the use of apolipoprotein C-I in the therapy and prevention of diseases wherein the amount of or binding ability of apolipoprotein C-I in the blood of sick persons is significantly different from that of normal persons. | 06-24-2010 |
20100167324 | Quantitative Assays for Ras p21 in Body Fluids - The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy. | 07-01-2010 |
20100196937 | CASCADE ENZYME-LINKED IMMUNOSORBENT ASSAY - The present invention relates to a cascade enzyme-linked immunosorbent assay, more precisely a cascade enzyme-linked immunosorbent assay using magnetic microparticles (MMPs) immobilized with the target antigen specific primary antibody and silica nanoparticles (SPs) immobilized with a cascade reaction initiator and the antigen-specific secondary antibody. When the method of the present invention is applied in the detection of an antigen in biosamples, the detection sensitivity can be significantly increased. | 08-05-2010 |
20100196938 | IMMUNOASSAY FOR VENOM DETECTION INCLUDING NONINVASIVE SAMPLE COLLECTION - Methods and immunoassays for diagnosing a bite or sting of a venomous organism in a patient having symptoms consistent with such a bite or sting are provided. A sample of venom is collected from the area of the suspected bite or sting using a swab and then contacted with an antibody that specifically binds to an antigenic site on venom present in the sample. Binding is then detected. The invention is illustrated by examples showing diagnosis of brown recluse spider bite, distinguishing it from other diagnoses with which it is often confused. This extremely sensitive test can detect venom antigens down to about 20 picograms even after the sample has been shipped and stored for periods of up to three weeks during the summer. | 08-05-2010 |
20100203560 | IMMUNOASSAY FOR QUANTIFICATION OF AN UNSTABLE ANTIGEN SELECTED FROM BNP AND proBNP - The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex. | 08-12-2010 |
20100221759 | ASSAY FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE RATIO OF GAMMA-SECRETASE ABETA CLEAVAGE PRODUCTS - Described is a method for the diagnosis of Alzheimer's disease (AD) or a particular stage of the disease which is based on the determination of the ratio of at least two gamma-secretase cleavage products, Abeta48, Abeta45, Abeta42, Abeta38 and Abeta35, preferably the ratio of Abeta38: Abeta42. A decreased ratio of Abeta38: Abeta42 as compared to the normal ratio is indicative of AD. Moreover, kits suitable for carrying out said diagnostic method are described. | 09-02-2010 |
20100221760 | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING sAPPbeta - The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided. | 09-02-2010 |
20100221761 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 09-02-2010 |
20100227343 | GLYCODELIN MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention. | 09-09-2010 |
20100233741 | IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS - The present specification discloses SNAP-25 immune response inducing compositions, methods of making α-SNAP-25 antibodies that selectively binds to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P | 09-16-2010 |
20100240078 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES - The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant. | 09-23-2010 |
20100248273 | AMELIORATION OF HETEROPHILE ANTIBODY IMMUNOSENSOR INTERFERENCE - The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 μg/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof. | 09-30-2010 |
20100248274 | ANTIBODY DIRECTED AGAINST PRO-GASTRIN RELEASING PEPTIDE, AND USE THEREOF - Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods. | 09-30-2010 |
20100248275 | METHODS FOR PREDICTING OUTCOME IN TRAUMATIC BRAIN INJURY - The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients. | 09-30-2010 |
20100267064 | METHODS FOR QUANTITATIVE TARGET DETECTION AND RELATED DEVICES AND SYSTEMS - Described herein is a method for detection of a target in a sample and related devices and systems. | 10-21-2010 |
20100304413 | DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER - Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL. | 12-02-2010 |
20110014639 | HYBRIDOMA CELL LINE PRODUCING MONOCLONAL ANTIBODY AGAINST FOOT-AND-MOUTH DISEASE VIRUS, THE MONOCLONAL ANTIBODY THEREFROM, IMMUNOASSAY REAGENT AND KIT, AND IMMUNOASSAY METHOD - Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus. | 01-20-2011 |
20110039283 | DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1 - The invention relates to a method for the diagnosis and/or risk stratification of cardiac diseases and diseases of the respiratory tract and lungs. According to said method, the free fragment N-terminal proEndothelin (NT-proET-1; AS 18-52 of the pre-proET according to FIG. | 02-17-2011 |
20110039284 | METHODS OF PROGNOSIS - The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample such as serum. | 02-17-2011 |
20110076704 | Method for diagnosing alzheimer's disease using serum glycoprotein as biomarker - It is an object of the present invention to detect a change in the metabolism of a glycoprotein having an α2,6-sialyl residue, which is contained in blood, so as to provide an agent and a method for diagnosing sporadic Alzheimer's disease. The present invention provides an agent for diagnosing Alzheimer's disease, which comprises lectin used for detecting an α2,6-sialyl residue-containing glycoprotein. | 03-31-2011 |
20110076705 | COMPOSITIONS AND METHODS FOR EARLY PREGNANCY DIAGNOSIS - Disclosed are antibodies and methods for detecting pregnancy in an animal. In certain aspects antibodies used binds immunologically to at least two PAGs selected from PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 and PAG21. Antibody encoding nucleic acids are also provided, as are kits, methods of use and additional antibody related compositions. | 03-31-2011 |
20110091914 | Immunological Test Element with Improved Control Zone - The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g., an enzyme, fluorescent or direct label, etc.) wherein the conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e., which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte. | 04-21-2011 |
20110091915 | IgA Nephropathy Testing Method and Test Kit - There is provided a renal disease testing method comprising a complex detection step of detecting a complex of human uromodulin and human IgA in a sample derived from urine collected from a subject. It is preferred that the renal disease testing method of the invention further comprises a determination step of assessing the whether the renal disease is IgA nephropathy based on the ratio of the amount of the complex detected in the complex detection step to the amount of urinary proteins in the sample. The renal disease testing method of the invention has good detection sensitivity and specificity, and can conveniently and safely assess the existence of a renal disease (preferably, IgA nephropathy). | 04-21-2011 |
20110104726 | Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 05-05-2011 |
20110117585 | Quantitative multiplex detection of pathogen biomarkers - The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel. | 05-19-2011 |
20110129861 | MEASUREMENT OF ANTI-CCP AND SERUM AMYLOID A METHOD TO ASSESS RHEUMATOID ARTHRITIS - The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention. | 06-02-2011 |
20110143382 | IgA Nephropathy Testing Method And Test Kit - There is provided a renal disease testing method comprising a complex detection step of detecting a complex of an antigen derived from human renal mesangial cells and human IgA in a sample derived from urine collected from a subject. It is preferred that the renal disease testing method of the invention further comprises a determination step of assessing the whether the renal disease is IgA nephropathy based on the ratio of the amount of the complex detected in the complex detection step to the amount of urinary proteins in the sample. The renal disease testing method of the invention has good detection sensitivity and specificity, and can conveniently and safely assess the existence of a renal disease (preferably, IgA nephropathy). | 06-16-2011 |
20110177538 | BIOMARKERS FOR RHEUMATOID ARTHRITIS (RA) - The invention provides methods for predicting and compositions for use in the prediction of rheumatoid arthritis (RA) based upon the simultaneous measurement of at least two biomarkers in a biological sample. The invention further relates to methods for following the efficiency of a treatment against RA and to methods for identifying test substances that are likely to prevent or diminish RA. | 07-21-2011 |
20110244495 | METHOD FOR TESTING ALZHEIMER'S DISEASE BY MEASURING DEGRADATION RATE OF -AMYLOID IN BLOOD AND DIAGNOSTIC REAGENT - Provided is a method of testing Alzheimer's disease using serum or plasma as a sample. It is found that a β-amyloid peptide added to a blood sample is degraded. The degradation activity thereof was compared between the blood samples of normal subjects and Alzheimer's disease patients, and it is also found that the degradation activity is significantly higher in the blood of the normal subjects. | 10-06-2011 |
20110256562 | METHODS FOR DIAGNOSING HEART FAILURE AND OTHER CARDIAC DISEASES - The invention relates to methods of diagnosing the severity of heart failure or a cardiac dysfunction in a subject. The invention further relates to monitoring the severity of heart failure in a subject and determining the prognosis of a subject that has suffered from heart failure. This invention also relates methods to identify patients at risk for cardiac dysfunction when exposed to cardiotoxic chemotherapy agents. | 10-20-2011 |
20110256563 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody. | 10-20-2011 |
20110262940 | CAPILLARY FOR IMMUNOASSAY, AND CAPILLARY IMMUNOASSAY METHOD USING SAME - A capillary for an immunoassay is provided which comprises an insoluble layer of an oxidase formed on an inner wall surface of said capillary, said oxidase being conjugated to a first antibody, and a layer of a hydrophilic polymer formed on said insoluble layer, said hydrophilic polymer layer containing a second antibody conjugated to a peroxidase, wherein said first and second antibodies are capable of binding to the same antigen. | 10-27-2011 |
20110262941 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 10-27-2011 |
20110287458 | METHOD AND COMPOSITION FOR THE DIAGNOSIS AND MONITORING OF INFLAMMATORY DISEASES - The present invention provides a canine S100 calcium binding protein useful in diagnosing an inflammatory disease. Also provided are methods of diagnosing an inflammatory disease by assaying a biological sample for the canine S100 calcium binding protein. The invention further provides antibodies specifically binding to the canine S100 calcium binding protein and related kits comprising the antibodies. | 11-24-2011 |
20110294148 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA. | 12-01-2011 |
20110306071 | Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase - The invention provides assays and methods for determining the substrate specificity of gamma secretase inhibitors and for identifying substrate-selective (and substrate isoform-selective) inhibitors of gamma secretase. The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a site specific or substrate specific manner. The invention provides isolated polypeptide sequences comprising modified gamma secretase substrates, and polynucleotide sequences encoding the polypeptide sequences. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. | 12-15-2011 |
20110312000 | MONOCLONAL ANTIBODY AND USE THEREOF - The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided. | 12-22-2011 |
20120009609 | DEVICES AND METHODS FOR DETECTING AMNIOTIC FLUID IN VAGINAL SECRETIONS - The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies. | 01-12-2012 |
20120009610 | ENDOSTATIN AS A MARKER OF HEART FAILURE - Disclosed is a method for assessing heart failure in an individual including the steps of a) measuring in a sample obtained from the individual the concentration of the marker endostatin, of b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. Also disclosed are the use of endostatin as a marker protein in the assessment of heart failure, a marker combination comprising endostatin, and a kit for measuring endostatin. | 01-12-2012 |
20120015387 | MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT - An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa. | 01-19-2012 |
20120021444 | METHOD FOR DIAGNOSIS OF CYSTIC FIBROSIS USING KL-6 LEVELS - The present invention provides a method for diagnosis of cystic fibrosis, the method comprising: measuring an amount of KL-6 in a sample of body fluid from a subject, and determining, based on the amount of KL-6 measured, the degree of presence of cystic fibrosis in the subject. | 01-26-2012 |
20120028281 | INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY - The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF. | 02-02-2012 |
20120034633 | MAGNETIC IMMUNOSENSOR AND METHOD OF USE - The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field. | 02-09-2012 |
20120040380 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE - The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a β-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a β-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a β-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a β-lactmase or instructions for using the components in an assay. | 02-16-2012 |
20120040381 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 02-16-2012 |
20120045783 | Method of determining tropomyosin in chitosan - A method capable of easily determining with high accuracy a protein in chitosan, the protein having a potential relevance to the development of an allergy, specifically tropomyosin and the content of the peptide. According to the method, tropomyosin is determined by immunoassay with the chitosan being in a state dissolved in an aqueous solution of an organic acid. The method also provides chitosan, which has a measurement value of the protein, specifically tropomyosin, not higher than a predetermined value as measured by the determination method and is assessed to have only a low risk of inducing the allergy. | 02-23-2012 |
20120077212 | METHODS OF DIAGNOSING ALS - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof. | 03-29-2012 |
20120115175 | METHODS FOR DIAGNOSING ELEVATED RIGHT OR LEFT VENTRICULAR FILLING PRESSURE - The present invention features a method of diagnosing elevated left or right ventricular filling pressure and cardiovascular dysfunction in a subject by detecting increased levels of sEng in a biological sample from the subject. | 05-10-2012 |
20120122128 | IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P | 05-17-2012 |
20120122129 | RAPID NASAL ASSAY KIT - The present invention relates to an assay which can be used on nasal secretions. The assay is used to determine the cause of nasal secretions, for example whether the secretions are due to an allergic reaction or a non-allergic reaction. | 05-17-2012 |
20120149042 | METHODS FOR PREDICTING OUTCOME IN TRAUMATIC BRAIN INJURY - The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients. | 06-14-2012 |
20120149044 | INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY - The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF. | 06-14-2012 |
20120164669 | MARKER PANEL FOR LEFT VENTRICULAR HYPERTROPHY - The present disclosure relates to methods, compositions, kits and devices for diagnosing, distinguishing and/or facilitating a therapeutic decision in a subject having left ventricular hypertrophy. In some aspects, the methods, compositions, kits and devices disclosed herein allow for diagnosing, distinguishing and/or facilitating a therapeutic decision in a subject having physiological left ventricular hypertrophy, and/or for a subject suffering from pathological left ventricular hypertrophy. | 06-28-2012 |
20120171704 | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor - A naturally-occurring soluble truncated IL-23Rα protein (i.e., Δ9 IL-23Rα) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23Rα protein. More particularly, antibody-sandwich ELISA method and kits for Δ9 IL-23Rα as an antigen were developed to detect Δ9 IL-23Rα levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma. | 07-05-2012 |
20120171705 | COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease. | 07-05-2012 |
20120178112 | METHOD OF DETECTING SKELETAL MUSCLE DAMAGE - The present invention relates to a method of detecting skeletal muscle damage and to the use of certain proteins and fragments thereof as biological markers (commonly known as “biomarkers”) for such damage. The present invention has particular reference to the detection of muscle toxicity in mammals, particularly humans. | 07-12-2012 |
20120183980 | KIT FOR AMPLIFYING DETECTED SIGNAL IN IMMUNOSENSOR AND METHOD FOR DETECTING TARGET ANTIGEN USING THE SAME - Disclosed is a kit for amplifying detected signal in immunosensor and a method for detecting target antigen using the same according to the present invention, whereby a target antigen can be effectively detected even by a small amount of target antibody to thereby reduce nonspecific detection signal and to detect an amplified signal. | 07-19-2012 |
20120183981 | METHOED FOR DETECTING CIRCULATING CARTILAGE OLIGOMERIC MATRIX PROTEIN IN THE DIAGNOSIS AND MONITORING OF CIRRHOSIS - The present invention is in the field of diagnostics, and in particular to the early diagnosis of liver cirrhosis in a patient not known to have liver cancer by detecting and measuring circulating cartilage oligomeric matrix protein (COMP) alone or in conjunction with one or more additional liver cirrhosis biomarkers in the biological fluid of a subject. | 07-19-2012 |
20120190051 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries. | 07-26-2012 |
20120202231 | SYNERGISTIC BIOMARKER ASSAY OF NEUROLOGICAL CONDITION USING S-100B - Processes and assays are provided for detecting and determining the magnitude of traumatic brain injury such as that from impact or percussive trauma or stroke. The inventive assays and processes recognize a synergistic correlation between detection of S-IOOb and one or more other injury specific biomarkers. | 08-09-2012 |
20120208217 | METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid. | 08-16-2012 |
20120208218 | METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid. | 08-16-2012 |
20120214185 | METHOD OF SCREENING MHC MOLECULES - The invention relates to a method for screening the binding properties of constituent peptides of MHC molecules by providing in solution MHC molecules or their constituent peptides for a set of MHC molecules including a plurality of subsets of MHC molecules, wherein the MHC molecules of each subset differ from MHC molecules of at least one other subset in at least one of the putative MHC binding peptide, an MHC alpha chain and an MHC beta chain, and loading said MHC molecules with an MHC binding peptide by (i) refolding of the MHC alpha chain and beta chain peptides in presence of said MHC binding peptide or (ii) by peptide exchange or loading with an unlabelled MHC binding peptide in the absence of any labelled MHC binding peptide, (b) taking of at least one sample from each subset, and (c) determining loading efficiency for the sample of step (b). | 08-23-2012 |
20120214186 | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING sAPPbeta - The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided. | 08-23-2012 |
20120244562 | METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS - Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals. | 09-27-2012 |
20120244563 | METHOD OF DETECTING PANCREATIC CANCER - To provide a method of accurately detecting pathological haptoglobin using a lectin having strong affinity and high specificity for fucose. The method of the present invention for detecting pancreatic cancer is characterized in that a fucose α1→6 specific lectin is allowed to act on pathological haptoglobin contained in a sample obtained from a living body, said lectin: (1) being extractede from basidiomycetes, (2) having a molecular weight of 4,000 to 40,000 as determined by the SDS polyacrylamide gel electrophoresis, and (3) having affinity for a fucose α1→6 sugar chain with a binding constant of 1.0×10 | 09-27-2012 |
20120264149 | METHOD FOR THE DETERMINATION OF THE FORMATION OF ENDOTHELINS FOR MEDICAL DIAGNOSTIC PURPOSES, AND ANTIBODIES AND KITS FOR CARRYING OUT SUCH A METHOD - An in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient for medical diagnostics purposes, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin, in particular a C-terminal peptide fragment. | 10-18-2012 |
20120270246 | PROCOLLAGEN C-PROTEINASE ENHANCER (PCPE) BIOMARKER FOR BONE FORMATION - A method of diagnosing fibrosis in a subject is provided, comprising the steps of: determining a level of PCPE in a body fluid sample obtained from said subject; and detecting an increased level of PCPE in said body fluid sample relative to a normal control level of PCPE, wherein said increased level of PCPE relative to normal control is indicative of fibrosis in said subject. Furthermore, methods for evaluating the pharmacological efficacy of a drug or a drug candidate in treatment of fibrosis in a patient and for monitoring change of fibrosis in a subject are provided. | 10-25-2012 |
20120276562 | 5.9 kDa PEPTIDE IMMUNOASSAY METHOD - Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the α-E chain and α chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes. | 11-01-2012 |
20120295288 | SEROLOGICAL MARKER FOR DETECTING PANCREATIC CANCER AND A METHOD FOR USING THE SEROLOGICAL MARKER - UL16 binding protein 2 (ULBP2) is a protein overexpressed in pancreatic cancer tissues, and the ULBP2 levels are significantly higher in pancreatic cancer patients than those in healthy controls. This invention provides a method to detect pancreatic cancer using ULBP2 as a serological marker. The combination of ULBP2 and CA19-9 promotes the efficacy of pancreatic cancer detection. When measuring the blood ULBP2 levels in patients with other cancer types, including colorectal carcinoma, nasopharyngeal carcinoma and gastric cancer illustrates the blood ULBP2 levels are higher in patients with pancreatic cancer than other cancer types. | 11-22-2012 |
20120295289 | DEVICE AND METHOD FOR CULTURING CELLS - A device and method for culturing cells is described. Culture media is continuously or intermittently delivered to the cell culture for diluting concentration of at least one marker component in the cell culture. The concentration of the marker component may be measured continuously or intermittently to determined the culture media delivery rate. | 11-22-2012 |
20120295290 | MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS - Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor. | 11-22-2012 |
20120301905 | TSH IMMUNOASSAYS AND PROCESSES FOR PERFORMING TSH IMMUNOASSAYS IN THE PRESENCE OF ENDOGENOUS CONTAMINANTS IN RESTRICTED WASH FORMATS - The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG). | 11-29-2012 |
20120301906 | TSH IMMUNOASSAYS EMPLOYING SCAVENGING REAGENTS FOR CROSS-REACTING ENDOCRINE GLYCOPROTEIN HORMONE ANALOGUES - The invention relates to Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogues such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG). | 11-29-2012 |
20120315655 | BIOMARKERS OF MUSCULOSKELETAL DISEASE - The present invention relates, in general, to biomarkers of musculoskeletal disease and, in particular, to methods of as diagnosing musculoskeletal disease, and/or predicting disease progression, by assaying for such biomarkers. The invention further relates to compounds and compositions suitable for use in such methods. | 12-13-2012 |
20120315656 | HYPERGLYCOSYLATED HCG DETECTION DEVICE - The present invention related to a pregnancy test device that can selectively detect hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample. The sample can be deposited on a proximal portion of the device for transport to a distal portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a capture site, in fluid communication with the release medium and formed of a second, different material. At least one of the release medium and the capture medium includes a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H. | 12-13-2012 |
20120322090 | SOLID PHASE-BOUND ELASTASE-BINDING ASSAY FOR THE MEASUREMENT OF ALPHA1-ANTITRYPSIN ACTIVITY - The present invention relates to a method for the measurement of active alpha | 12-20-2012 |
20120329079 | Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk - A method for assessing risk of prostate cancer utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination is provided. Also provided is a method for assessing risk of cancer utilizing Pro108 or specific antibodies to Pro108. Antibodies that bind to Pro108 on a mammalian cell in vivo and compositions comprising an anti-Pro108 antibody and a carrier which can be provided in an article of manufacture or a kit are also provided. An isolated nucleic acid encoding an anti-Pro108 antibody, an expression vector comprising the isolated nucleic acid, cells that produce the anti-Pro108 antibodies and a method of producing the anti-Pro108 antibodies as well as methods for use of the antibodies in killing an Pro108-expressing cancer cell and alleviating or treating an Pro108-expressing cancer in a mammal are also provided. | 12-27-2012 |
20120329080 | ANTI-HLA ASSAY AND METHODS - Anti-MHC assay methodologies utilize functionally active, recombinantly produced, truncated individual soluble MHC trimolecular complexes that are linked to a substrate. | 12-27-2012 |
20130004976 | HUMAN INSULIN ASSAY AND ASSAY REAGENT - A problem of the present invention is to provide an antibody specific to human insulin and an assay and an assay reagent using the antibody capable of accurately assaying human insulin without being affected by porcine insulin. The present invention provides an assay and an assay reagent capable of specifically assaying human insulin by combining a monoclonal antibody specifically reactive with human insulin and nonreactive with porcine insulin and a different anti-human insulin antibody. | 01-03-2013 |
20130004977 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 01-03-2013 |
20130004978 | ANTI-LG3 ANTIBODIES AND USES THEREOF - A method for the prediction of the risk and/or the diagnosis of vascular damage such as acute vascular rejection in a subject, based on the determination of anti-LG3 antibodies levels in a sample from the subject, is disclosed. | 01-03-2013 |
20130022998 | GLYCODELIN MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention. | 01-24-2013 |
20130029363 | METHOD FOR DIAGNOSING MALIGNANT TUMOR - To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. | 01-31-2013 |
20130040325 | Enzyme Linked Immunosorbent Assay (ELISA) Method and Kit for Detecting Soluble Programmed Cell Death Protein 5 (PDCD5) - An enzyme linked immunosorbent assay (ELISA) method and kit for detecting soluble programmed cell death 5 (PDCD5) protein are provided. The method includes the following steps: (1) contacting a sample to be tested with a solid carrier loaded with a first antibody of PDCD5 protein; (2) adding a second antibody of PDCD5 protein, which is capable to binding to a detecting label; (3) adding the detecting label and detecting the bound detecting label. The soluble PDCD5 in a biological sample from a mammal comprising human can be detected by the ELISA method and kit. The method and kit can be used for detecting the level of PDCD5 protein in plasma, serum, urine, cerebrospinal fluid and synovial fluid so that an auxiliary detection method, for diagnosis of autoimmune disease, inflammation (such as hepatitis), and tumor etc., determination of disease course, observation of therapeutic effect and prognosis and medical guidance, is provided. | 02-14-2013 |
20130045494 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Immumoglobulin A, Metalloproteinase inhibitor 4, and Thrombomodulin as diagnostic and prognostic biomarker assays in renal injuries. | 02-21-2013 |
20130045495 | ELISA FOR VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index. | 02-21-2013 |
20130052671 | IL-6 DETECTION BASED EARLY DIAGNOSIS AND PREDICTION OF SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME AND SEPSIS IN ASYMPTOMATIC PATIENTS - Methods, systems and kits for the early diagnosis or prediction of systemic inflammatory response syndrome (SIRS) including sepsis in asymptomatic patients, such as patients undergoing a surgical intervention, are provided. Some embodiments include a method and system for the detection or diagnosis of SIRS, or detection or diagnosis of a risk to suffer from or develop SIRS, in an asymptomatic patient comprising the steps of determining the level of IL-6 (or a variant thereof) in a sample from the patient; comparing the level of IL-6 (or a variant thereof) to a reference level; detecting or diagnosing SIRS or diagnosing a risk to suffer from or develop SIRS, wherein the sample is isolated at least 2 times at short intervals and the determining and comparing steps are both repeated for each sample. Also provided are methods, systems and kits for therapy monitoring and mortality prediction. | 02-28-2013 |
20130071865 | Devices And Methods For Detecting Amniotic Fluid In Vaginal Secretions - The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies. | 03-21-2013 |
20130078655 | KIDNEY PROGNOSTIC ASSAY - The invention provides a method of predicting subjects at risk of loss of kidney function and/or identifying subjects at greater risk of loss of kidney function, and/or identifying subjects at risk of kidney failure/end stage kidney disease, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with increased risk of loss of kidney function and/or increased risk of renal failure/end stage kidney disease. A further aspect of the invention provides a method of monitoring renal impairment, comprising detecting an amount of free light chains (FLC) in a sample from a subject having renal impairment and comparing the amount of FLC in the sample with an Total FLC amount of FLC detected in a sample previously obtained from the subject, wherein an increase in the amount FLC detected, compared to the previous sample, indicates an increase in the risk of loss of renal function in the subject, and a decrease in the amount of FLC indicates a decrease in the risk of loss of renal function in the subject. | 03-28-2013 |
20130078656 | ARTIFICIAL IMMUNE SYSTEM: METHODS OF USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system. | 03-28-2013 |
20130078657 | HYPERTHERMIA AUGMENTED IN-VITRO IMMUNE RECOGNITION - The present invention relates to a method for generation of a test-antigen specific cell-mediated immune response by incubating at hyperthermic conditions and, more particularly, a method for generation of a test-antigen specific cell-mediated immune response by incubating at hyperthermic conditions and optionally adding IL-7 and/or blocking IL-10. Even more particularly, the present invention provides a method for generating a cell-mediated response to an antigen using whole blood or other suitable bio-logical samples. The method is useful in for immune diagnosis of many infectious diseases, as a marker of immunocompetence, and for detection of T-cell responses to non-self antigens (i.e. infections and vaccines). | 03-28-2013 |
20130084587 | Levels of cytokeratins in blood and body fluids as biomarkers for cancer screening, diagnosis and treatment monitoring - Cytokeratins are intermediate filaments in the epithelial cells. Human cancers are malignant counterparts of normal epithelia. Human cancer cells express various kinds of cytokeratins dependent upon the specific cancer cell type. Pathologists have been using cytokeratin immunostaining for classification of tumor origins and cancer types. We claim that the protein levels of cytokeratin 7 (CK7) in the blood and/or body fluids are proportional to the tumor burden, and these protein levels of CK7 can be used as biomarkers for cancer screening, diagnosis and treatment monitoring. | 04-04-2013 |
20130095508 | INSTRUMENTED PIPETTE - A pipette component for use in performing an experimental procedure with a fluid sample and a pipette, the pipette component including: a pipette interface configured to engage sealingly and separably with a body of the pipette; a tip interface configured to engage sealingly and separably with a replaceable tip; and an experiment region configured to receive at least part of the fluid sample by operation of the pipette, and configured to perform at least part of the experimental procedure in the experiment region using the at least part of the fluid sample. | 04-18-2013 |
20130115639 | METHOD FOR DETECTING A SALMONELLA INFECTION - The invention relates to a diagnostic method to detect a salmonellae infection and/or salmonellae contamination. Fields of use include medicine, veterinary medicine and various branches of industry. | 05-09-2013 |
20130115640 | ACTH for Treatment of Kidney Disease - Provided herein are methods for prophylactic treatment of Diabetes Mellitus comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing Diabetes Mellitus. Also provided herein are methods for monitoring treatment of Diabetes Mellitus by measuring and monitoring levels of MCP-1, TGF-β, VEGF A and VEGF B. | 05-09-2013 |
20130122530 | PREDICTION AND RECOGNITION OF ACUTE KIDNEY INJURY AFTER SURGERY - Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject. | 05-16-2013 |
20130130288 | Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers - This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. | 05-23-2013 |
20130137124 | DIAGNOSTIC TEST TO EXCLUDE SIGNIFICANT RENAL INJURY - Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associate lipocalin (NGAL) are provided. | 05-30-2013 |
20130143245 | RECOMBINANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERIVED FROM HUMAN MYOCARDIUM - Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65. | 06-06-2013 |
20130149726 | POTENCY TEST FOR VACCINE FORMULATIONS - The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen. | 06-13-2013 |
20130157296 | RECOMBINANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERVIVED FROM HUMAN MYOCARDIUM - Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65. | 06-20-2013 |
20130157297 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha-2-HS-glycoprotein, Interleukin-9, Leukemia inhibitory factor, Macrophage colony-stimulating factor 1, Prolactin, and Stromal cell-derived factor 12 as diagnostic and prognostic biomarkers in renal injuries. | 06-20-2013 |
20130171672 | Methods for Detecting Oncofetal Fibronectin - Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronectin for selection of concepti are | 07-04-2013 |
20130171673 | PIPETTE TIP, PIPETTE SYSTEM AND METHOD FOR PERFORMING ANALYSIS WITH THE PIPETTE TIP AND SYSTEM - The present invention relates to a pipette tip ( | 07-04-2013 |
20130183698 | IMMUNOCHROMATOGRAPHY DEVICES, METHODS AND KITS - A membrane-based assay device, methods and kits for determining the presence or quantity of an analyte in a test sample are provided. The immunochromatographic device comprises a membrane having a capture antibody bound thereto at a test zone, wherein the capture antibody is capable of binding with an analyte, in particular a Z-AAT protein present in a sample from a PiZ gene carrier. | 07-18-2013 |
20130210041 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries. | 08-15-2013 |
20130210042 | DIAGNOSTIC AND PROGNOSTIC METHOD FOR HUMAN TAUOPATHIES - The present invention relates to a method for the diagnosis and/or prognosis of tauopathies, in particular Alzeimer's disease. The method is based on the detection and quantification of a 20-22 kDa NH2-tau fragment. | 08-15-2013 |
20130210043 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries. | 08-15-2013 |
20130217049 | Methods and Systems for Signal Amplification of Bioassays - Disclosed herein are methods and systems for the detection of an analyte of interest by an amplified assay. The method and systems of the invention utilize the high specificity of biomolecules that have been coupled to a solid support to further amplify a signal produced by the interaction of a binding agent with the analyte of interest as a means to detect low levels of the analyte of interest present in a sample. In certain embodiments, for immunochemical (for example, ELISA or RIA) or immunofluorescence assays in which a protein to be identified is bound directly or through capture antibodies to a passivated surface, amplification of ˜10,000-fold can be achieved. | 08-22-2013 |
20130217050 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING-SOLUBLE GPVI - Provided are an agent for noninvasively and easily diagnosing Alzheimer's disease, a method for diagnosing Alzheimer's disease through the measurement, and a measurement kit therefor. The present invention relates to a reagent for measuring soluble GPVI (sGPVI) in a human body fluid; an agent for specifically diagnosing Alzheimer's disease, said agent comprising a reagent for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid; and a method for specifically diagnosing Alzheimer's disease, said method comprising a step for measuring the concentration of sGPVI in a collected human body fluid and a step for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid. | 08-22-2013 |
20130224776 | PCan065 Antibody Compositions and Methods of Use - The invention provides isolated anti-PCan065 antibodies that bind to PCan065. The invention also encompasses compositions comprising an anti-PCan065 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PCan065 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PCan065 antibodies. The invention encompasses a method of producing the anti-PCan065 antibodies. Other aspects of the invention are a method of killing an PCan065-expressing cancer cell, comprising contacting the cancer cell with an anti-PCan065 antibody and a method of alleviating or treating an PCan065-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PCan065 antibody to the mammal. | 08-29-2013 |
20130230871 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Interleukin-5, Interleukin-6 receptor subunit beta, Tissue factor, Sex hormone-binding globulin, Alpha-2-macroglobulin, Apolipoprotein A-I, Calcitonin, Thrombopoietin, C-reactive protein, Intercellular adhesion molecule 3, Macrophage metalloelastase, Apolipoprotein B-100, and Fibrinogen as diagnostic and prognostic biomarkers in renal injuries. | 09-05-2013 |
20130236918 | SANDWICH ASSAY FOR IMMUNOSUPPRESSANT DRUGS - Methods are disclosed for determining an immunosuppressant drug in a sample suspected of containing an immunosuppressant drug. The method includes providing in combination in a medium the sample, a first monoclonal antibody for the immunosuppressant drug, and a second monoclonal antibody for the immunosuppressant drug. The second monoclonal antibody binds to a portion of the immunosuppressant drug other than the portion to which the first monoclonal antibody binds to the immunosuppressant drug. The medium is incubated under conditions for binding of the first monoclonal antibody and the second monoclonal antibody to the immunosuppressant drug. The medium is examined for the presence of an immunocomplex comprising the immunosuppressant drug, the first monoclonal antibody and the second monoclonal antibody. The presence and/or amount of the immunocomplex indicates the presence and/or amount of the immunosuppressant drug in the sample. | 09-12-2013 |
20130236919 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING MOOD DISORDERS - The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated or reduced levels of Aβ protein, including Aβ | 09-12-2013 |
20130252267 | URINE AND SERUM BIOMARKERS ASSOCIATED WITH DIABETIC NEPHROPATHY - Described are uses of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof. | 09-26-2013 |
20130288280 | ALZHEIMER'S DIAGNOSIS - Evaluation of VLP-1 levels in combination with at least one of amyloid-β peptide (Aβ), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease. | 10-31-2013 |
20130295594 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CROHN'S DISEASE - The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated. | 11-07-2013 |
20130309699 | ANTIBODY PURIFICATION VIA AFFINITY CHROMATOGRAPHY - Embodiments herein provide methods of purifying monoclonal and polyclonal anti-bodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid. | 11-21-2013 |
20130330752 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Angiopoietin-related protein 3, Soluble Lymphatic vessel endothelial hyaluronic acid receptor 1, and Vascular endothelial growth factor D as diagnostic and prognostic biomarkers in renal injuries. | 12-12-2013 |
20130344517 | USE OF GALECTIN-3 FOR RISK ASSESSMENT AND DETECTION OF PREECLAMPSIA AND RELATED CONDITIONS - Described herein are materials and methods for predicting and/or monitoring preeclampsia and related conditions, including eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, left ventricular dysfunction, and heart failure, in a pregnant or post-partum woman. More specifically, use of the endogenous protein galectin-3 in predicting and/or monitoring preeclampsia and related conditions in a pregnant or post-partum woman is described. Also described are methods of preventing and/or treating preeclampsia and related conditions by inhibiting galectin-3. | 12-26-2013 |
20140004545 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | 01-02-2014 |
20140017713 | METHOD OF DIAGNOSING CANCER AND DIAGNOSIS KIT USING MEASUREMENT OF NK CELL ACTIVITY - Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject. | 01-16-2014 |
20140030745 | ASSAY KIT AND ANALYSIS METHOD - An assay kit for reacting with an analyte includes a plurality of reaction vessels and a plurality of micro beads. Each of the reaction vessels contains a filter membrane with a plurality of pores, and the diameter of each micro bead is greater than that of each pore. Each of the micro beads is directly or indirectly bound to the analyte, the competitor of the analyte or the identifying molecule. Additionally, an analysis method applied with the assay kit is also disclosed. | 01-30-2014 |
20140045200 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 02-13-2014 |
20140051100 | METHOD OF THERAPY - Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also relates to methods of determining when a therapy to treat a disease characterized by the production of regulator cells should be administered to a patient. | 02-20-2014 |
20140057307 | METHOD FOR THE DIAGNOSIS OF DRY EYE AND BLEPHARITIS - The invention relates to a method for the diagnosis of dry eye or blepharitis in a subject which is based on the detection of one or more proteins in a sample from said subject. The invention also relates to a method for differentiating dry eyes and blepharitis. | 02-27-2014 |
20140065648 | USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE - Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments. | 03-06-2014 |
20140072989 | TSH IMMUNOASSAYS EMPLOYING SCAVENGING REAGENTS FOR CROSS-REACTING ENDOCRINE GLYCOPROTEIN HORMONE ANALOGUES - Thyroid Stimulating Hormone (TSH) immunoassays are performed using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogues such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG). | 03-13-2014 |
20140080157 | MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES - Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex. In some embodiments, the proteomic profile may also include information on the expression of adiponectin, sex hormone binding globulin (SHBG), C-reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof. | 03-20-2014 |
20140080158 | METHOD FOR IMMUNOLOGICALLY MEASURING SOLUBLE LR11 - To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). | 03-20-2014 |
20140120563 | ALLERGEN TESTING PLATFORM FOR USE WITH MOBILE ELECTRONIC DEVICES - An allergy testing system for use with a mobile electronic device having a camera includes a housing that can be attached to the mobile electronic device. First and second light sources within the housing are configured to illuminate, respectively, a test sample and a control sample. A colorimetric assay is performed on the test sample and the control sample. The first light source and the second light source are activated and the camera of the mobile electronic device captures images of transmitted light. The relative intensity of transmitted light is then used by software loaded on the mobile electronic device to determine a relative absorbance value. The relative absorbance value is used, together with a calibration curve, to measure the concentration of a particular allergen within the test sample. Based on the concentration of the allergen the test sample can be labeled as either “positive” or “negative.” | 05-01-2014 |
20140141459 | PENTRAXIN 3 ASSOCIATION WITH ASTHMA - The present invention relates to methods of utilizing pentraxin 3 as a marker for therapeutic efficacy in preclinical models of asthma. | 05-22-2014 |
20140147867 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND RISK PREDICTION IN HEART FAILURE - The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby. | 05-29-2014 |
20140147868 | COBALAMIN ASSAY - The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates. | 05-29-2014 |
20140193845 | USE OF SFRP-3 IN THE ASSESSMENT OF HEART FAILURE - Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3. | 07-10-2014 |
20140220606 | MICROFLUIDIC ASSAY DEVICES AND METHODS - Microfluidic microplate devices and methods for assay systems such as immunoassays, to achieve improvements particularly of higher sensitivity and more repeatable performance, are disclosed. In preferred embodiments, also disclosed are the use of a range of coating buffers for the capture antibody and the use of coating buffers with specific formulations within very narrow ranges to achieve optimal results in the use of the devices and methods. | 08-07-2014 |
20140220607 | SIGNAL AMPLIFICATION FOR IMMUNOASSAYS BY USE OF AVIDIN-BIOTIN LINKAGES - In sandwich-type immunoassays that capture a protein analyte between a capture antibody, typically bound to a solid phase, and a detection antibody that is coupled to a reporter group, the number of reporter groups associated with each molecule of analyte is increased by a variety of methods that utilize avidin-biotin-type binding in conjunction with such features as immunological binding to the reporter group on the detection antibody or multiple biotin-avidin-type binding sites. | 08-07-2014 |
20140234878 | COMPOSITION FOR DIAGNOSING ACUTE MYOCARDIAL INFARCTION, KIT FOR DIAGNOSING ACUTE MYOCARDIAL INFARCTION COMPRISING SAME, AND METHOD OF DIAGNOSING ACUTE MYOCARDIAL INFARCTION - Provided are compositions for diagnosing acute myocardial infarction including a preparation for measuring an amount of a substance P (SubP) or neuropeptide Y (NpY), kits for diagnosing acute myocardial infarction comprising the composition, and methods of diagnosing acute myocardial infarction based on the amount of the substance P or the neuropeptide Y. | 08-21-2014 |
20140234879 | DYNAMIC OF SFLT-1 OR ENDOGLIN/PLGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME - Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3. | 08-21-2014 |
20140248644 | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A - The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum. | 09-04-2014 |
20140255958 | MEMBRANE SENSOR CAPABLE OF SEQUENTIALLY CHANGING REACTION CONDITION BY SINGLE SAMPLE INJECTION - Disclosed herein are a membrane sensor capable of changing a reaction condition by a single sample injection and a method for measuring a reaction using the same, and more specifically, a membrane sensor designed so that a bio reaction having two or more reaction conditions is sequentially generated by a single sample injection, by forming an asymmetric membrane between a reactant storing part and a reaction membrane. | 09-11-2014 |
20140273035 | ASSAY WITH INCREASED DYNAMIC RANGE - Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations. | 09-18-2014 |
20140322734 | BIOMARKERS FOR PREDICTION, DIAGNOSIS, AND MONITORING OF PARKINSON'S DISEASE - A method for the risk detection, early diagnosis, prognosis, and monitoring of Parkinson's disease in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with Parkinson's disease, or an earlier sample from the individual of interest. | 10-30-2014 |
20140335549 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 11-13-2014 |
20140342381 | DEVICES AND METHODS FOR BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITION - The present invention relates to an exemplary in vitro diagnostic (IVD) device used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, cerebrospinal fluid (CSF). The inventive IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format wither to a display device or to a storage device internal or external to the IVD. | 11-20-2014 |
20140342382 | METHOD FOR THE DETECTION OF A BINDING PARTNER OF A MULTISPECIFIC BINDER - Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase. | 11-20-2014 |
20140349323 | ANTI-DRUG ANTIBODY ASSAY - The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay. | 11-27-2014 |
20140363833 | AFFINITY-BASED DETECTION OF LIGAND-ENCODED SYNTHETIC BIOMARKERS - The invention relates to methods and products associated with in vivo enzyme profiling. In particular, biomarker nanoparticles capable of quantitatively detecting enzymatic activity in vivo are described. These nanoparticles can be used to detect in vivo enzyme activity. The invention also relates to products, kits, and databases for use in the methods of the invention. | 12-11-2014 |
20140363834 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Growth/differentiation factor 2, Catalase, Vascular endothelial growth factor C, and Melanoma-derived growth regulatory protein as diagnostic and prognostic biomarkers in renal injuries. | 12-11-2014 |
20140370532 | QUANTITATIVE MULTIPLEX DETECTION OF PATHOGEN BIOMARKERS - The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel. | 12-18-2014 |
20140370533 | METHOD OF DETECTING ACTIVE TB - A method of detecting active TB in a patient comprising providing at least one peptide comprising an amino acid sequence with at least 80% sequence identity to a sequence selected from SEQ. ID NOS. 1 to 8, or an antigenic fragment thereof and contacting the peptide with a biological sample obtained from the patient. The presence of an antibody in the sample binding to the peptide is indicative of active TB in the patient. | 12-18-2014 |
20150010929 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries. | 01-08-2015 |
20150010930 | Reagents, Kits And Methods, For Detecting Biological Molecules By Energy Transfer From An Activated Chemiluminescent Substrate To An Energy Acceptor Dye - Reagents, kits and methods for detecting biological molecules by energy transfer from an activated chemiluminescent substrate to an energy acceptor dye such as a J-aggregated dye are described. | 01-08-2015 |
20150017668 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING MOOD DISORDERS - The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated or reduced levels of Aβ protein, including Aβ | 01-15-2015 |
20150024421 | NUMBER OF IL4 AND/OR IL13 SECRETING T-CELLS AS A BIOMARKER FOR ALLERGIC DISEASES - The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease. | 01-22-2015 |
20150031056 | DEVELOPMENT OF SPECIFIC IMMUNOASSAY CRITICAL REAGENTS FOR PHARMACOKINETIC ASSESSMENTS OF PEPTIDE POLYMERS IN PRECLINICAL AND CLINICAL MATRICES - The present disclosure provides methods of developing a specific immunoassay for the Pharmacokinetic assessments of peptides, peptide oligomer and polymer including Glatiramer Acetate (GA), also known as Copolymer 1, Copolymer-1, Cop 1 or Cop in the clinical and preclinical matrices. | 01-29-2015 |
20150031057 | METHOD FOR THE DETERMINATION OF RENAL FUNCTION - Method for the determination of the renal function wherein the amount of at least one agrin fragment derived by neurotrypsin cleavage of agrin is measured in a sample taken from a patient and the measured amount of the agrin-fragment in the sample is used as indicator for renal function. | 01-29-2015 |
20150037825 | Means and Methods for Assessing Hematopoietic Toxicity - The present invention pertains to the field of diagnostics for hematopoietic toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing hematopoietic toxicity. It also relates to a method for determining whether a compound is capable of inducing such hematopoietic toxicity in a subject and to a method of identifying a drug for treating hematopoietic toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing hematopoietic toxicity. | 02-05-2015 |
20150037826 | STANDARD FOR QUANTIFYING PATHOGENIC AGGREGATES FROM PROTEINS PRODUCED NATURALLY IN THE BODY - The invention relates to standards for quantifying pathogenic aggregates or oligomers of endogenous proteins which characterize a protein aggregation disease, amyloid degeneration or protein misfolding diseases and use of these standards for quantifying these pathogenic aggregates or oligomers. | 02-05-2015 |
20150044708 | Methods for Detecting Oncofetal Fibronectin - Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronectin for selection of concepti are | 02-12-2015 |
20150050674 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect Chitinase-3-like protein 1 as a predictive biomarker in renal injuries. | 02-19-2015 |
20150050675 | C1q-ADIPONECTIN COMPLEX AND USE THEREOF - An object of the present invention is to provide a biomarker that can be used as a precise diagnostic marker for MetS or arteriosclerosis risk. | 02-19-2015 |
20150056641 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Trefoil factor 3 as diagnostic and prognostic biomarker assays in renal injuries. | 02-26-2015 |
20150056642 | ARMET AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro. | 02-26-2015 |
20150079615 | USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE - Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments. | 03-19-2015 |
20150111231 | ANTI-sAPPbeta ANTIBODY - Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP β or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPPβ contained in a biological sample. | 04-23-2015 |
20150111232 | Soluble B7-H1 - This document features methods of evaluating mammals by assessing expression of B7-H1 in a body fluid. | 04-23-2015 |
20150118699 | METHOD FOR DETECTING DISSEMINATED INTRAVASCULAR COAGULATION OR INFECTIOUS DISSEMINATED INTRAVASCULAR COAGULATION - Markers useful in diagnosing disseminated intravascular coagulation (DIC) or infectious DIC are provided. In a method for detecting DIC of the present invention, sCD14-ST in a sample is measured. In a method of detecting infectious DIC of the present invention, sCD14-ST and a coagulation-related marker in a sample are measured. | 04-30-2015 |
20150125886 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM - A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T | 05-07-2015 |
20150132781 | MULTIPLEXED CHROMATOGRAPHY-IMMUNOASSAY METHOD FOR THE CHARACTERIZATION OF CIRCULATING IMMUNE COMPLEXES - Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (CICs) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-SEC chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type III hypersensitivity reaction/immune complex-mediated disease. | 05-14-2015 |
20150132782 | METHOD FOR DIAGNOSING CANCER BY DETECTING GPC3 - Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample. | 05-14-2015 |
20150140582 | Immunological Test Element with Improved Control Zone - The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g. an enzyme, fluorescent or direct label etc.) wherein said conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e. which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte. | 05-21-2015 |
20150290639 | PRESSURE ASSISTED LATERAL FLOW DIAGNOSTIC DEVICE - An external pressure assisted lateral flow diagnostic test device, and method for use thereof, for highly sensitive detection of species of interest. The microfluidic test device comprises a sample and reagent chambers, a detection channel comprising an encapsulated porous membrane with an analyte capture zone, wherein a dynamic pressure causes fluid to flow from the sample and reagent chambers through the detection channel. | 10-15-2015 |
20150299283 | NOVEL PEPTIDE AND APPLICATION THEREOF - An object of the present invention is to discover a novel component of the renin-angiotensin system (RAS) and to provide the same as a novel biomarker of a cardiovascular disease or a renal disease. This invention provides a novel peptide associated with the renin-angiotensin system comprising the amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence derived therefrom by deletion, substitution, or addition of one to several amino acids other than the asparagine residue at position 14 and an N-linked glycan added thereto at the asparagine residue at position 14. With the use of such peptide as a biomarker, a renal disease or a cardiovascular disease can be diagnosed at an early stage in a simple manner without imposing burdens on a subject. | 10-22-2015 |
20150299311 | POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF - We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell. | 10-22-2015 |
20150301056 | METHYLGLYOXAL AS A MARKER OF CANCER - A reliable, sensitive and easy to handle diagnostic and prognostic test of cancer, includes measuring and analyzing the production of methylglyoxal (MG) from metabolically active cancer cells; in biological samples of extracellular fluids, cells and/or tissues of human or animal subjects. It uses any chemical or immunological in vitro method for MG measurement and it provides a kit for the early detection, screening and diagnosis of cancer; for the staging of cancer, for predicting the survival odds of cancer patients, for monitoring therapeutic response to anticancer programs (including prevention and prophylactic treatments), and for prediction and early detection of cachexia. | 10-22-2015 |
20150301057 | ASSAY TO MEASURE MIDKINE OR PLEIOTROPHIN LEVEL FOR DIAGNOSING A GROWTH - The invention provides methods and kits for diagnosing a growth in a subject by providing a sample of a growth taken from a subject, determining the level of midkine or pleiotrophin in the sample by an immunoassay, and comparing the level of midkine or pleiotrophin determined from the sample with a control. An increased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a malignant growth, whereas an equivalent or decreased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a benign growth. Growth refers to, for example, papillary thyroid cancer (PTC). | 10-22-2015 |
20150309027 | MONOCLONAL ANTIBODIES SPECIFIC FOR CRY1CA AND RELATED DETECTION METHODS - Described herein are murine monoclonal antibodies and methods useful for determining and quantitating the presence of Cry1Ca delta endotoxin. The claimed antibodies specifically bind the core toxin region making them suitable for detecting the native full length Cry1Ca toxin as well as the amino core toxin and N-terminal 29 residue truncated forms. | 10-29-2015 |
20150309032 | Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor - Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment. | 10-29-2015 |
20150323526 | IMMUNOCHROMATOGRAPHY DEVICES, METHODS, AND KITS - A membrane-based assay device, methods and kits for determining the presence or quantity of an analyte in a test sample are provided. The immunochromatographic device comprises a membrane having a capture antibody bound thereto at a test zone, wherein the capture antibody is capable of binding with an analyte, in particular a Z-AAT protein present in a sample from a PiZ gene carrier. | 11-12-2015 |
20150346207 | A method for predicting the risk of getting cancer or diagnosing cancer in a subject - Subject matter of the present invention is a method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject comprising:
| 12-03-2015 |
20150355197 | BIOMARKERS FOR DIAGNOSING LIVER DISEASE - The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. | 12-10-2015 |
20150361178 | Method and Kit for Detecting 1,25-Dihydroxyvitamin D and Related Antibodies - There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method of the invention, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method of the invention. The assay of the invention is preferably a sandwich immunoassay. | 12-17-2015 |
20150362494 | METHOD FOR DETECTING A COLORECTAL LESION - The invention relates to a method for detecting a colorectal lesion likely to evolve into invasive colorectal cancer, in a patient, by determining the presence of Liver Fatty Acid-Binding Protein (LFABP), in a biological sample of the patient, distant form the lesion. | 12-17-2015 |
20160011186 | Systems And Methods For Electronic Detection With Nanofets | 01-14-2016 |
20160018401 | METHODS OF PROGNOSIS - The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample such as serum. | 01-21-2016 |
20160018412 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries. | 01-21-2016 |
20160018420 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS - The technology described herein is directed to the diagnosis and treatment of androgen disorders and/or deficiencies, e.g. low testosterone. | 01-21-2016 |
20160025718 | NOVEL ASSAY - The invention relates to a method for detection of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19, and/or soluble fragments thereof, in a sample, comprising the steps of contacting said sample with a solid phase having immobilized thereon a first antibody having specificity for cytokeratin 8, a second antibody having specificity for cytokeratin 18 and, optionally,a third antibody having specificity for a first epitope of cytokeratin 19; allowing cytokeratin and/or soluble fragments thereof in said sample to bind to said first, second and optionally third antibodies thereby forming complexes; contacting said complexes with a first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and optionally a second labelled antibody having specificity for a second epitope of cytokeratin 19; allowing said first and second labelled antibodies to bind to said complexes; and detecting said first labelled antibody and said second labelled antibody bound to said complexes. The invention further relates to a method for quantitative determination of soluble fragments of at least two of cytokeratin 8, 18 and 19 in a sample and to a kit-of-parts for performing the method according to the invention. | 01-28-2016 |
20160025719 | HIGHLY SENSITIVE IMMUNOASSAY FOR RAPID QUANTIFICATION OF MENINGOCOCCAL CAPSULAR POLYSACCHARIDE ANTIGENS - The present disclosure relates to the field of immunoassays for Gram negative bacteria, in particular | 01-28-2016 |
20160033517 | ELISA FOR VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index. | 02-04-2016 |
20160046707 | NEUTRALIZING ANTI-CCL20 ANTIBODIES - The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer. | 02-18-2016 |
20160047806 | SIMPLIFIED EXTRACTION METHODS FOR THE RAPID DETERMINATION OF SPECIES CONTENT OF ADIPOSE TISSUE BASED ON THE DETECTION OF TNI IN IMMUNOASSAYS - A method for extracting protein from a fat-containing sample is described comprising the steps of separating solidified fat and solid residues from a centrifuged mixture of protein, fat, other solid materials and aqueous solution of phosphate buffered saline to form an aqueous phase containing the protein. The aqueous phase is then filtered through a filter to separate a clear protein extract from the mixture. | 02-18-2016 |
20160054317 | ASSAY WITH INCREASED DYNAMIC RANGE - Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations. | 02-25-2016 |
20160084843 | IN VITRO METHOD FOR THE EARLY DETECTION OF A POTENTIAL INFLAMMATION, IN PARTICULAR ASSOCIATED WITH REJECTION OF A TRANSPLANT, A NEURODEGENERATIVE DISORDER OR A DEPRESSION - An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems. | 03-24-2016 |
20160103134 | DEVICE AND METHOD FOR SEPARATING AND ANALYZING BLOOD - The invention provides a device for detecting FABP in a blood sample from a patient, methods for analyzing blood on the presence of FABP, as well as methods and kits for the detection of FABP in a blood sample from a patient. | 04-14-2016 |
20160109442 | NOVEL TEST METHOD FOR RHEUMATOID ARTHRITIS AND KIT FOR RHEUMATOID ARTHRITIS TEST - Provided are: a novel test method for rheumatoid arthritis; and a kit for rheumatoid arthritis test, which is used in the novel test method for rheumatoid arthritis. A test method for rheumatoid arthritis according to the present invention is characterized by comprising a step for measuring the amount of talin in the plasma or serum of an animal subject. This measurement is carried out, for example, by an immunological method using an antibody which binds to talin. A kit for rheumatoid arthritis test according to the present invention is used for such a test method and contains, for example, a solid-phase carrier to which an antibody that binds to talin is affixed. | 04-21-2016 |
20160109444 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CROHN'S DISEASE - The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated. | 04-21-2016 |
20160109465 | TSH IMMUNOASSAYS AND PROCESSES FOR PERFORMING TSH IMMUNOASSAYS IN THE PRESENCE OF ENDOGENOUS CONTAMINANTS IN RESTRICTED WASH FORMATS - The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG). | 04-21-2016 |
20160109466 | TSH ANTIBODIES FOR POINT-OF-CARE IMMUNOASSAY FORMATS - The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG). | 04-21-2016 |
20160116475 | ELISA Detection of Urine DEK to Predict and Diagnose Bladder Cancer in Humans - The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans. | 04-28-2016 |
20160124002 | METHOD FOR DETECTING HYPOXIA OR DIAGNOSING HYPOXIA-RELATED DISEASES - The present invention provides a composition, kit, and method for detecting hypoxia or diagnosing hypoxia-related diseases, the composition containing a material for detecting arachidonic acid and a derivative thereof. The composition, kit, and method according to the present invention can conveniently and promptly detect hypoxia through the detection of a biomarker in a biological sample, and thus can be useful in the prevention or early diagnose of diseases caused by hypoxia, the determination of the severity of diseases and therapeutic effects, tracking of diseases, or the like. | 05-05-2016 |
20160131663 | BIOMARKER FOR PSYCHIATRIC AND NEUROLOGICAL DISORDERS - The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free κ immunoglobulin chains, free λ immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects. The biomarker enables more effective tests and diagnoses to be conducted combining inflammatory cytokines in the blood of patients with psychiatric and neurological disorders. | 05-12-2016 |
20160146809 | PEPTIDES AND METHODS FOR THE DETECTION OF LEISHMANIASIS - The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus | 05-26-2016 |
20160146835 | THERAPEUTIC AGENT, METHOD OF TREATMENT AND METHOD FOR PREDICTING THE SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS), DISEASES CAUSED OR ACCOMPANIED BY NEUTROPHIL ACTIVATION - The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject. | 05-26-2016 |
20160146844 | COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID - Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. | 05-26-2016 |
20160161476 | Modular Fluid Dispensing Devices - The present disclosure provides devices which deliver fluids from several reservoirs to a reaction vessel and eventually to a waste chamber in a predetermined schedule. The device provides improved simplicity while improving operational robustness and flexibility. | 06-09-2016 |
20160169884 | DEVICE AND METHOD FOR BIOLOGICAL ANALYSES | 06-16-2016 |
20160377615 | METHOD FOR EVALUATION OF FUNCTION OF PHAGOCYTE - A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte. | 12-29-2016 |
20160377632 | METHOD FOR DIGANOSING ATHEROSCLEROTIC PLAQUES BY MEASUREMENT OF CD36 - The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed. | 12-29-2016 |
20180021773 | ASSAY DEVICES, METHODS FOR CARRYING OUT ASSAYS, ASSAY KITS AND METHOD FOR MANUFACTURING ASSAY DEVICES | 01-25-2018 |
20190145976 | Antibodies With High Affinity For Alpha-Klotho | 05-16-2019 |
20220137071 | METHOD AND KIT FOR MEASURING APP669-711 - A method of measuring APP669-711, including involving immobilizing, to a support, a first antibody capable of immunospecifically binding to an N terminus of APP669-711; blocking the support to which the first antibody is immobilized, with a blocking agent; bringing APP669-711 in the sample into contact with the first antibody thus immobilized, and thereby allowing APP669-711 to bind to the first antibody; removing the sample that is not bound; bringing a second antibody capable of immunospecifically binding to a C terminus of APP669-711, into contact with APP669-711 bound to the first antibody thus immobilized, and thereby allowing the second antibody to bind to APP669-711; removing the second antibody that is not bound; and detecting the presence of the second antibody bound to APP669-711. | 05-05-2022 |